GHRP-1
Overview
Growth Hormone Releasing Peptide-1 is a synthetic hexapeptide belonging to the growth hormone secretagogue family. It acts as a weak agonist at the ghrelin receptor (GHS-R1a) to stimulate pulsatile growth hormone release from the anterior pituitary. GHRP-1 has limited potency compared to later-generation secretagogues and served primarily as a prototype for subsequent drug development.
Key Research Findings
Early pharmacological studies in healthy volunteers demonstrated modest growth hormone release with reduced potency relative to GHRP-2 and GHRP-6. The compound has not advanced to pivotal clinical trials due to its limited efficacy and the availability of more potent analogs. It remains a research tool for studying growth hormone secretion pathways.
Subcutaneous injection, Intravenous
Research Phase
Interested in GHRP-1?
Find a verified provider experienced with GHRP-1 protocols in your area. All providers are credentialed and use compliant sourcing.
Find a GHRP-1 ProviderRelated Peptides
CJC-1295
In Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, extending its half-life from minutes to approximately 6-8 days. CJC-1295 stimulates pulsatile GH release from the anterior pituitary by binding to GHRH receptors while preserving the natural GH secretory pattern and negative feedback mechanisms.
Ipamorelin
In Clinical TrialsA highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH release. Unlike other GH secretagogues, ipamorelin does not significantly affect ACTH, cortisol, or prolactin levels, making it one of the most specific GH-releasing peptides. It works synergistically with GHRH analogs like CJC-1295.
Sermorelin
FDA ApprovedA synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid hormone. Sermorelin stimulates the pituitary to produce and release growth hormone through the natural GHRH receptor pathway, preserving the hypothalamic-pituitary feedback axis. It maintains physiological pulsatile GH secretion patterns.
Tesamorelin (Egrifta)
FDA ApprovedA synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability. Tesamorelin specifically targets visceral adipose tissue reduction by stimulating lipolysis through GH-mediated pathways. It is the only FDA-approved treatment for HIV-associated lipodystrophy.